Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Administered obinutuzumab under the approved indications in Korea at investigator's discretion
Previously untreated with obinutuzumab
You may not be if
Out-of locally approved indications, dosage, and administration
Pregnant women, breastfeeding women
Hepatic disease
Participate in other clinical trials
Clareo Health | Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia
